Q2 Earnings Estimate for ClearPoint Neuro Issued By B. Riley

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Analysts at B. Riley dropped their Q2 2025 EPS estimates for shares of ClearPoint Neuro in a report released on Tuesday, May 13th. B. Riley analyst A. Schock now expects that the company will post earnings of ($0.20) per share for the quarter, down from their prior estimate of ($0.14). B. Riley currently has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro’s Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, Q1 2026 earnings at ($0.17) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.65) EPS.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus lifted their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. Lake Street Capital lifted their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, January 21st.

ClearPoint Neuro Price Performance

Shares of CLPT opened at $13.18 on Friday. The firm’s 50 day moving average is $12.87 and its 200-day moving average is $14.22. The stock has a market capitalization of $368.90 million, a P/E ratio of -19.10 and a beta of 1.03. ClearPoint Neuro has a 12-month low of $5.11 and a 12-month high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The company had revenue of $8.49 million for the quarter, compared to the consensus estimate of $8.21 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CLPT. Barclays PLC increased its position in shares of ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company’s stock worth $64,000 after acquiring an additional 1,109 shares in the last quarter. JPMorgan Chase & Co. grew its position in ClearPoint Neuro by 58.7% during the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after purchasing an additional 3,612 shares in the last quarter. Conway Capital Management Inc. grew its position in ClearPoint Neuro by 13.9% during the fourth quarter. Conway Capital Management Inc. now owns 161,225 shares of the company’s stock valued at $2,480,000 after purchasing an additional 19,725 shares in the last quarter. Parsons Capital Management Inc. RI grew its position in ClearPoint Neuro by 1.9% during the fourth quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company’s stock valued at $2,177,000 after purchasing an additional 2,600 shares in the last quarter. Finally, R Squared Ltd purchased a new position in ClearPoint Neuro during the fourth quarter valued at approximately $32,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.